Search

Your search keyword '"Odintsov, Igor"' showing total 207 results

Search Constraints

Start Over You searched for: Author "Odintsov, Igor" Remove constraint Author: "Odintsov, Igor"
207 results on '"Odintsov, Igor"'

Search Results

1. Towards a Visual-Language Foundation Model for Computational Pathology

8. Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations

11. Combination Therapy With MDM2 and MEK Inhibitors Is Effective in Patient-Derived Models of Lung Adenocarcinoma With Concurrent Oncogenic Drivers and MDM2 Amplification

14. Author Correction: Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations

17. The Elbrus-4C Based Node as Part of Heterogeneous Cluster for Oil and Gas Processing Researches

18. Myxoid Inflammatory Myofibroblastic Sarcoma: Clinicopathologic Analysis of 25 Cases of a Distinctive Sarcoma With Deceptively Bland Morphology and Aggressive Clinical Behavior.

19. Performance and Energy Analysis of Nighttime Satellite Image Archive Processing Module

20. The Energy Consumption Analysis for the Multispectral Infrared Satellite Images Processing Algorithm

21. The Hardware Configuration Analysis for HPC Processing and Interpretation of the Geological and Geophysical Data

23. Prevalence and Therapeutic Targeting of High Level ERBB2 Amplification in Non-Small Cell Lung Cancer

26. The Elbrus Platform Feasibility Assessment for High-Performance Computations

28. Abstract 6127: MDM2 inhibition in combination with MEK inhibition in pre-clinical models of lung adenocarcinomas with MDM2 amplification

29. Supplementary Table from Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements

30. Abstract 4007: Efficacy of vepafestinib in preclinical models of RET fusion-driven sarcoma models

31. Supplementary Figure from Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements

32. Data from Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements

36. Figure S1 from Therapeutic Potential of NTRK3 Inhibition in Desmoplastic Small Round Cell Tumor

38. Supplementary Figure S3 from The Anti-HER3 mAb Seribantumab Effectively Inhibits Growth of Patient-Derived and Isogenic Cell Line and Xenograft Models with Oncogenic NRG1 Fusions

40. Supplementary Materials and Methods from The Anti-HER3 mAb Seribantumab Effectively Inhibits Growth of Patient-Derived and Isogenic Cell Line and Xenograft Models with Oncogenic NRG1 Fusions

43. Comparison of TAS0953/HM06 and selpercatinib in RET fusion-driven preclinical disease models of intracranial metastases.

46. Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements

47. Novel patient-derived models of desmoplastic small round cell tumor confirm a targetable dependency on ERBB signaling

49. Functional impact and targetability of PI3KCA, GNAS, and PTEN mutations in a spindle cell rhabdomyosarcoma with MYOD1 L122R mutation

Catalog

Books, media, physical & digital resources